U.S. Pain Management Market Size, Share & Forecast 2026–2032

ID: MR-11364 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: U.S. Pain Management Market
  • ✓Market Size 2024: USD 61.4 billion
  • ✓Market Size 2032: USD 92.6 billion
  • ✓CAGR: 5.3%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Non-Opioid Launch Reshapes Prescribing: Vertex's Journavx (suzetrigine), approved by the FDA in January 2025, is the first NaV1.8 pain inhibitor cleared for acute pain. Its uptake depends on Medicare Part D formulary placement, which will determine substitution rates across 68 million Medicare beneficiaries.
FINDING 02
Settlements Fund Pain Growth: Most investors assume tighter opioid rules shrink this market, yet the USD 50 billion multistate opioid settlements are funding interventional pain services, nonopioid procurement and spinal cord stimulator demand at Medtronic and Boston Scientific.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Part D Formulary Access: Manufacturers and device makers should file Part D formulary requests ahead of the June 2026 bid deadline, prioritizing nonopioid analgesics with NaV1.8 mechanisms. Early positioning secures Medicare access before competing entrants reach formulary parity in 2027.

Pain Management in the United States: Market Overview

The U.S. pain management market was valued at USD 61.4 billion in 2024 and is projected to reach USD 92.6 billion by 2032, driven by a chronic pain population exceeding 50 million adults according to CDC estimates. Its structure divides into branded and generic analgesics, interventional devices, and outpatient pain services. Government has shaped this market's current form more than any other actor, particularly through Medicare reimbursement under the Social Security Act and DEA scheduling under the Controlled Substances Act of 1970.

The private sector has led innovation in devices and nonopioid drugs, with Medtronic and Boston Scientific dominating spinal cord stimulation and Vertex Pharmaceuticals advancing NaV1.8 chemistry. Government has been dominant in controlling opioid demand. The CDC's 2016 prescribing guideline and its 2022 successor reduced high-dose opioid initiation, shifting spending toward multimodal and interventional alternatives. Private payers and state Medicaid programs then translated these signals into formulary rules.

Policy-Driven Growth in US Pain Management

The SUPPORT for Patients and Communities Act (Public Law 115-271, enacted October 2018) requires Medicare Part D to strengthen opioid safety edits and expands coverage for opioid use disorder treatment, shifting prescribing toward multimodal regimens. Quantity limits and prescriber alerts push clinicians toward nonopioid analgesics and interventional options that fall outside those edits. This regulatory pressure converts directly into prescription volume growth for nonopioid products and procedure-based pain services.

Medicare Administrative Contractors apply Local Coverage Determinations for spinal cord stimulation, requiring documented failure of conservative therapy before implant. This documentation requirement channels patients through multidisciplinary pain clinics, lifting implant volumes for Medtronic and Boston Scientific. Third, more than USD 50 billion in multistate opioid settlements, negotiated with McKesson, Cardinal Health, Cencora and Johnson & Johnson, funds state abatement programs that finance treatment capacity and alternative pain services.

Regulatory Barriers and Compliance Costs in American Pain Care

Prescribers must hold a DEA registration under the Controlled Substances Act (21 U.S.C. 801 et seq.) plus a state controlled-substance license in every jurisdiction where they practice, with a three-year federal registration fee of USD 888. The Drug Enforcement Administration sets Schedule II aggregate production quotas annually, constraining opioid supply and extending manufacturing lead times. Telemedicine prescribing of controlled substances continues under temporary flexibilities that the DEA extended through 31 December 2025, forcing clinics to plan compliance around a shifting regulatory calendar.

FDA's Opioid Analgesic Risk Evaluation and Mitigation Strategy requires manufacturers to fund prescriber education, and the FDA's 2023 safety labeling changes added long-term use warnings that raised label-update costs. Nearly all states mandate Prescription Drug Monitoring Program queries before opioid prescribing, adding documentation time to every initial encounter. Each mandatory check adds labor cost for clinics that operate on thin margins under Medicare fee schedules.

Policy-Created Opportunities in US Pain Care

The NIH HEAL Initiative, launched in 2018 with multi-year appropriations exceeding USD 1 billion, funds nonopioid pain research across the National Institutes of Health and related agencies. The FDA's January 2025 approval of Journavx created the first commercial test case for this funding pipeline. Developers of NaV1.8 and other nonopioid mechanisms now have a regulatory precedent and a federal research base to build on.

The Consolidated Appropriations Act, 2021 authorized Medicare Part B coverage of acupuncture for chronic lower back pain, with coverage phased in from 2025. The MISSION Act of 2018 (Public Law 115-182) expanded community care for veterans, directing Department of Veterans Affairs referrals to private pain clinics and nonopioid providers. Both policies create reimbursed demand for nonpharmacologic and community-based pain services.

Market at a Glance

MetricDetail
Market Size 2024USD 61.4 billion
Market Size 2032USD 92.6 billion
Growth Rate (CAGR)5.3%
Most Critical Decision FactorMedicare Part D formulary placement for nonopioid analgesics
Largest RegionSouth Census Region
Competitive StructureConsolidated in branded drugs; fragmented in generics and clinics

Leading Market Participants

  • Johnson & Johnson
  • Pfizer
  • Vertex Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Mallinckrodt
  • Hikma Pharmaceuticals
  • Medtronic
  • Boston Scientific
  • AbbVie
  • Collegium Pharmaceutical

Regulatory and Policy Environment for US Pain Management

The primary legislation is the Controlled Substances Act (Public Law 91-513, 1970), administered by the Drug Enforcement Administration, which classifies opioid analgesics by schedule and mandates registration, recordkeeping, and quota compliance. The Federal Food, Drug, and Cosmetic Act governs drug approval and labeling through the FDA's Center for Drug Evaluation and Research. CMS administers Medicare coverage and payment, while state boards of pharmacy enforce PDMP reporting and prescribing limits. Compliance therefore spans three federal agencies and up to fifty state regimes.

The DEA's special registration rule for telemedicine, proposed in January 2025, is expected to finalize during 2026, replacing temporary flexibilities. The Medicare Part D bid deadline for plan year 2027 falls on the first Monday in June 2026, setting formulary composition for nonopioid products. Compared with Canada, where Health Canada regulates controlled substances under the Controlled Drugs and Substances Act (S.C. 1996, c. 19), the U.S. framework imposes more layered federal and state registration obligations on prescribers.

Long-Term Policy Outlook for US Pain Management

By 2032, the Inflation Reduction Act's Medicare drug price negotiation cycles will extend to a broader set of branded drugs from 2027 onward, applying pricing pressure to high-cost branded analgesics and biologics. Opioid settlement payments scheduled through the late 2030s will continue funding state abatement programs, sustaining demand for treatment and alternative pain services. These two forces together will shift revenue away from branded opioid products toward devices, nonopioid drugs, and procedure-based care.

Regulators are expected to tighten opioid quota and prescribing oversight while expanding coverage for nonopioid pathways, including NaV1.8 therapies and interventional procedures. DEA telemedicine rules will determine whether remote pain management scales beyond metropolitan clinics. Market leaders will be those that align clinical evidence with Medicare coverage decisions, making payer engagement a core operating competency through 2032.

Frequently Asked Questions

The Drug Enforcement Administration controls opioid supply through Schedule II classification, aggregate production quotas, and prescriber registration under the Controlled Substances Act. CMS and state boards of pharmacy add prescribing and reporting limits on top of these federal controls.
The DEA proposed a special registration framework in January 2025 to govern controlled-substance prescribing via telemedicine after temporary flexibilities lapsed. A final rule is expected during 2026, and clinics must monitor its terms before scaling remote pain services.
The Opioid Analgesic Risk Evaluation and Mitigation Strategy requires manufacturers to fund prescriber education and maintain safety labeling. Non-compliance can trigger enforcement action under the Federal Food, Drug, and Cosmetic Act.
The Consolidated Appropriations Act, 2021 authorized Medicare Part B coverage of acupuncture for chronic lower back pain, with coverage phased in from 2025. Providers must meet CMS enrollment and billing requirements to receive reimbursement.
Settlement proceeds flow to state abatement programs that finance treatment capacity, prevention, and alternative pain services. Allocation rules vary by state settlement agreement, so providers should verify eligibility with their state attorney general's office.

Market Segmentation

By Drug Class
  • Opioid Analgesics
  • Non-Steroidal Anti-Inflammatory Drugs
  • Neuropathic Pain Agents
  • Novel Non-Opioid Analgesics
  • Adjuvant Analgesics
By Care Setting
  • Hospitals
  • Ambulatory Surgical Centers
  • Dedicated Pain Clinics
  • Home and Telehealth Care

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Pain Management - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Drug Class Insights
4.1 Opioid Analgesics
4.2 Non-Steroidal Anti-Inflammatory Drugs
4.3 Neuropathic Pain Agents
4.4 Novel Non-Opioid Analgesics
4.5 Others
Chapter 05 Care Setting Insights
5.1 Hospitals
5.2 Ambulatory Surgical Centers
5.3 Dedicated Pain Clinics
5.4 Home and Telehealth Care
5.5 Others
Chapter 06 Competitive Landscape
6.1 Market Players
6.2 Leading Market Participants
6.2.1 Johnson & Johnson
6.2.2 Pfizer
6.2.3 Vertex Pharmaceuticals
6.2.4 Teva Pharmaceutical Industries
6.2.5 Mallinckrodt
6.2.6 Hikma Pharmaceuticals
6.2.7 Medtronic
6.2.8 Boston Scientific
6.2.9 AbbVie
6.2.10 Collegium Pharmaceutical
6.3 Regulatory Environment
6.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.